A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

Phase 1/2 Completed 36 enrolled Abivax S.A.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and pharmacodynamics.

Timeline

Start: 2017-03-27
Primary completion: 2018-12-27
Completion: 2019-10-21

Publications

Moron-Lopez S, Bernal S, Wong JK, Martinez-Picado J, Yukl SA. ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy-Suppressed Individuals Living With HIV. Clin Infect Dis. 2022 Jun 10;74(11):2044-2049. doi: 10.1093/cid/ciab733.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Obefazimod	Small molecule	50 mg	Oral
Subject	Obefazimod	Small molecule	150 mg	Oral

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

Summary

Timeline

Publications

Drugs

Indications